On Sept. 19, U.S. Reps. Morgan Griffith (R-VA) and Brett Guthrie (R-KY) sent a letter to Food and Drug Administration (FDA) Commissioner Dr. Robert Califf to clarify regulatory processes surrounding cannabidiol (CBD), CBD-derived products, and tobacco products.
© Shutterstock
In the letter, the Congressmen said the FDA’s approach to CBD has created “unnecessary uncertainty” surrounding these products.
“The United States currently has a robust but largely unregulated CBD market, which leads to an unsafe marketplace for consumers,” the Congressmen wrote. “Consumer products that contain CBD – such as dietary supplements, food, and beverages – are currently sold across the country under a patchwork of state laws and regulations that have been developed and promulgated in light of FDA’s inaction. This has even led to multiple cases of children purchasing over-the-counter CBD gummies with unsafe levels of delta-8 THC and suffering harm as a result. This is due to the FDA’s failure to regulate and enforce statutory standards established by Congress that govern CBD and CBD-derived products.”
The Congressmen wrote that despite legislation passed in 2018 that removed hemp-derived CBD from the Controlled Substances Act, CBD is still subject to FDA regulatory authority and is prohibited from being used in any dietary supplements or as a food or beverage additive. They said that the agency has yet to create any regulatory direction for CBD and CBD-derived…
